Abstract:The Bayesian optimal interval (BOIN) design is a novel phase I trial design for finding the maximum tolerated dose (MTD). It can be used to conduct both single-agent and drug-combination trials. The BOIN design is motivated by the top priority and concern of clinicians, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. The most important advantage of the BOIN design is that it is easy to implement in practice and has superior operating characteristics. The BOIN design is algorithm-based and thus can be implemented in a way similar to the traditional “3+3” design. The performance of the BOIN design is comparable to that of the continual reassessment method (CRM, one of the best performing model-based phase I trial designs) in terms of selecting the MTD, but has a lower risk of assigning patients to subtherapeutic or overly toxic doses (i.e., better patient ethics). The idea behind the BOIN design is straightforward. The conduct of phase I trials can be viewed as a sequence of decision-making steps of dose assignment for patients who are sequentially enrolled into a trial. At each moment of decision making, based on the observed data, we take one of three actions: escalate, deescalate or retain the current dose. Under the standard assumption that efficacy monotonically increases with toxicity (for cytotoxic agents), an ideal trial design would escalate the dose when the current dose is below the MTD in order to avoid treating a patient at a subtherapeutic dose level; deescalate the dose when the current dose is above the MTD in order to avoid exposing a patient to an overly toxic dose; and retain the same dose level when the current dose is equal (or close) to the MTD. However, such an ideal design is not available in practice because we do not know whether the current dose is actually below, above or equal (or close) to the MTD, and need to

Generalized triple outcome decision-making in basket trials

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

Decision-making with multiple correlated binary outcomes in clinical trials

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trials

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Incorporating Historical Information to Improve Phase I Clinical Trials

A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints

A Comprehensive Toolbox to Facilitate Quantitative Decision Science in Drug Development: A web-based R shiny application GOahead

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

TODIM Method Based on Cumulative Prospect Theory for Multiple Attributes Group Decision Making Under Probabilistic Hesitant Fuzzy Setting

Augmented Binary Method for Basket Trials (ABBA)